Want to read (8)
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management
Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ, ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis.
Am J Respir Crit Care Med · 2011
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ.
Nat Biotechnol · 2011
Genetic screens in human cells using the CRISPR-Cas9 system
Wang T, Wei JJ, Sabatini DM, Lander ES.
Science · 2014
Cognitive reserve in ageing and Alzheimer's disease
Stern Y.
Lancet Neurol · 2012
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA, Carter SL, Getz G, Stemke-Hale K, Mills GB, Verhaak RG.
Nat Commun · 2013
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G, Dubois B, Dufouil C, Ellis KA, van der Flier WM, Glodzik L, van Harten AC, de Leon MJ, McHugh P, Mielke MM, Molinuevo JL, Mosconi L, Osorio RS, Perrotin A, Petersen RC, Rabin LA, Rami L, Reisberg B, Rentz DM, Sachdev PS, de la Sayette V, Saykin AJ, Scheltens P, Shulman MB, Slavin MJ, Sperling RA, Stewart R, Uspenskaya O, Vellas B, Visser PJ, Wagner M, Subjective Cognitive Decline Initiative (SCD-I) Working Group.
Alzheimers Dement · 2014
Phases of A beta-deposition in the human brain and its relevance for the development of AD
Thal DR, Rüb U, Orantes M, Braak H.
Neurology · 2002
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R, Virgin HW, Listgarten J, Root DE.
Nat Biotechnol · 2016